MAC lung disease can affect the lungs in two different ways. One, known as nodular bronchiectatic, causes tiny knots to develop within the smaller airways and air sacs of the lungs. Over time, the ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

The incidence of infection by Mycobacterium abscessus is increasing in patients with cystic fibrosis, chronic obstructive ...

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a small-cap biotech currently valued at $37.32 million, disclosed that its Phase 3 study of epetraborole for MAC lung disease did not meet the primary ...

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

A Chinese man's bizarre habit of sniffing his dirty socks landed him in hospital after it led to him developing a serious fungal infection in his lungs. The unnamed man, described as an 'ordinary ...

Researchers have developed next-generation rifamycin analogs that effectively kill both replicating and nonreplicating Mycobacterium abscessus while minimizing drug-drug interactions. Lead candidates ...

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the ...

MENLO PARK, Calif. - AN2 Therapeutics, Inc. (NASDAQ:ANTX), a small-cap biotech currently valued at $37.32 million, disclosed that its Phase 3 study of epetraborole for MAC lung disease did not meet ...